Company is developing a novel humanized anti IL-15R antibody to target depletion of resident memory T-cells. It hopes to launch early human trials in 2021/2.
VALLAURIX / Clinuvel Pharmaceuticals
Parvysmelanotide (VLRX001) contains a specific peptide sequence, designed to make it less susceptible to degradation than physiologic (natural) alpha-melanocyte stimulating hormone (α-MSH).
Bioniz Therapeutics / Almirall BNZ-1 for an immuno-dermatology franchise in vitiligo, cutaneous T-cell Lymphoma and alopecia areata. The lead product candidate has completed Phase 1 SAD and MAD clinical trials in healthy volunteers and is currently in Phase1/2a clinical development in CTCL.
Company in-licensed topical compound BOS-475 (formerly GSK3183475) to treat vitiligo and psoriasis. This Phase I-ready compound is a small molecule inhibitor of Bromodomain and Extra-Terminal. It reduces the expression of pro-inflammatory mediators, such as IL-17 and Th1-associated chemokines.
AXIM Biotechnologies Drug candidate AX-1602. Company filed patent application for a method to treat vitiligo with a topical composition containing cannabidiol and cannabigerol. Specific details not yet available.
ARRIEN Pharmaceuticals Company develops an orally available JAK3 inhibitor ARN-4079, which targets unique Cys909 residue at the gatekeeper position. The company plans to file for IND to treat vitiligo and other skin diseases. It is currently seeking partnerships that will help it fulfill IND-enabling studies and Phase I clinical trials.
ACHE Laboratorios Farmaceuticos The Brazilian regulatory agency - ANVISA - has requested back in 2016 the cancellation of the Phase 3 study for drug candidate ACH24 study for conducting a Phase 1 study first. Specific details not yet available.
Company is actively seeking partnerships to advance TT-01 development, a DNA-based therapy for vitiligo. It uses a modified HSP70i developed by Prof. Caroline Le Poole at Northwestern and Loyola Universities.
Company is focused on suppressing T-cell effector responses for lupus and vitiligo. It aims to modulate metabolic pathways in immune cells — mainly CD4 and CD8 T cell subtypes.
Company filed patent application for melanocortin receptor-1 peptides (MC-1) back in 2013. Specific details not yet available.
LSI (Life Science Investments)
Company is pre-clinical trials for VITILSI. This is the only plant-based, cosmeceutical formulation in the pipeline with antioxidant, anti-inflammatory and immunomodulatory properties, combined with melanogenesis-inducing properties of Coleus forskohlii root and Cassia alata leaves extract.
CASTLE CREEK Pharma Drug candidate CCP-070 is in the preclinical stage for a ‘rare dermatologic condition’. The company in-licensed these tri- and tetra-peptide melanotropic analog series from Prof. Abdel-Malek at the University of Cincinnati. Promising peptide structures are small enough to achieve dermal penetration after topical application.